

Avy Violari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6911245/publications.pdf>

Version: 2024-02-01

55
papers

2,808
citations

361413

20
h-index

175258

52
g-index

57
all docs

57
docs citations

57
times ranked

2571
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Antiretroviral Therapy and Mortality among HIV-Infected Infants. <i>New England Journal of Medicine</i> , 2008, 359, 2233-2244.	27.0	1,273
2	Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. <i>Lancet</i> , The, 2013, 382, 1555-1563.	13.7	213
3	Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children. <i>New England Journal of Medicine</i> , 2012, 366, 2380-2389.	27.0	172
4	Early antiretroviral therapy improves neurodevelopmental outcomes in infants. <i>Aids</i> , 2012, 26, 1685-1690.	2.2	155
5	A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. <i>Aids</i> , 2005, 19, 1289-1297.	2.2	82
6	A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. <i>Nature Communications</i> , 2019, 10, 412.	12.8	73
7	Early severe HIV disease precedes early antiretroviral therapy in infants: Are we too late?. <i>Journal of the International AIDS Society</i> , 2014, 17, 18914.	3.0	65
8	Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trial. <i>Aids</i> , 2018, 32, 189-204.	2.2	57
9	Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy. <i>Aids</i> , 2014, 28, 531-541.	2.2	55
10	Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 803-809.	9.1	47
11	Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 1113-1121.	5.8	41
12	Effect of in-utero HIV exposure and antiretroviral treatment strategies on measles susceptibility and immunogenicity of measles vaccine. <i>Aids</i> , 2013, 27, 1583-1591.	2.2	40
13	Stigma, Depression, and Substance Use Problems Among Perinatally HIV-Infected Youth in South Africa. <i>AIDS and Behavior</i> , 2018, 22, 3892-3896.	2.7	33
14	Increased Microbial Translocation in 180 Days Old Perinatally Human Immunodeficiency Virus-positive Infants as Compared With Human Immunodeficiency Virus-exposed Uninfected Infants of Similar Age. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 877-882.	2.0	32
15	Five year neurodevelopment outcomes of perinatally HIV-infected children on early limited or deferred continuous antiretroviral therapy. <i>Journal of the International AIDS Society</i> , 2018, 21, e25106.	3.0	32
16	Dating Violence Against HIV-Infected Youth in South Africa: Associations With Sexual Risk Behavior, Medication Adherence, and Mental Health. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 64-71.	2.1	32
17	Extent of disclosure: what perinatally HIV-infected children have been told about their own HIV status. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 378-386.	1.2	28
18	Thymic Output and CD4 T-Cell Reconstitution in HIV-Infected Children on Early and Interrupted Antiretroviral Treatment: Evidence from the Children with HIV Early Antiretroviral Therapy Trial. <i>Frontiers in Immunology</i> , 2017, 8, 1162.	4.8	25

#	ARTICLE	IF	CITATIONS
19	Childhood adversity increases the risk of onward transmission from perinatal HIV-infected adolescents and youth in South Africa. <i>Child Abuse and Neglect</i> , 2018, 79, 98-106.	2.6	25
20	African Multi-Site 2-Year Neuropsychological Study of School-Age Children Perinatally Infected, Exposed, and Unexposed to Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, e105-e114.	5.8	23
21	Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by <i>Streptococcus pneumoniae</i> during the primary series of immunization. <i>Vaccine</i> , 2011, 29, 6994-7001.	3.8	20
22	Routine viral load monitoring in HIV-infected infants and children in low- and middle-income countries: challenges and opportunities. <i>Journal of the International AIDS Society</i> , 2017, 20, e25001.	3.0	20
23	Risk Factors for Adverse Birth Outcomes in the PROMISE 1077BF/1077FF Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 521-532.	2.1	19
24	Distinct epigenetic profiles in children with perinatally-acquired HIV on antiretroviral therapy. <i>Scientific Reports</i> , 2019, 9, 10495.	3.3	18
25	Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 143-150.	1.3	18
26	Safety and Efficacy of Darunavir/Ritonavir in Treatment-experienced Pediatric Patients. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e132-e137.	2.0	14
27	Low Vitamin-D Levels Combined with PKP3-SIGIRR-TMEM16J Host Variants Is Associated with Tuberculosis and Death in HIV-Infected and -Exposed Infants. <i>PLoS ONE</i> , 2016, 11, e0148649.	2.5	14
28	Biomarkers of Aging in HIV-Infected Children on Suppressive Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 549-556.	2.1	13
29	Growing up positive: adolescent HIV disclosure to sexual partners and others. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 1565-1572.	1.2	13
30	Comparison of dried blood spot and plasma sampling for untargeted metabolomics. <i>Metabolomics</i> , 2021, 17, 62.	3.0	13
31	Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial. <i>AIDS Research and Therapy</i> , 2021, 18, 63.	1.7	13
32	Mental Health of Adolescents in the Era of Antiretroviral Therapy: Is There a Difference Between HIV-Infected and Uninfected Youth in South Africa?. <i>Journal of Adolescent Health</i> , 2020, 67, 76-83.	2.5	12
33	Effect of HIV exposure and timing of antiretroviral therapy initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and hepatitis B vaccines. <i>Expert Review of Vaccines</i> , 2019, 18, 95-104.	4.4	11
34	Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. <i>HIV Clinical Trials</i> , 2018, 19, 209-224.	2.0	10
35	Implementation of a PMTCT programme in a high HIV prevalence setting in Johannesburg, South Africa: 2002-2015. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1024.	0.9	9
36	Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the C children with HIV Early Antiretroviral Therapy (CHER) Study. <i>BMC Research Notes</i> , 2011, 4, 448.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Mitochondrial Impairment in Well-Suppressed Children with Perinatal HIV-Infection on Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 27-38.	1.1	8
38	Recovery of HIV encephalopathy in perinatally infected children on antiretroviral therapy. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 1309-1316.	2.1	8
39	Starting HIV-positive Babies on Antiretroviral Treatment: Perspectives of Mothers in Soweto, South Africa. <i>Journal of Pediatric Health Care</i> , 2010, 24, 176-183.	1.2	7
40	Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 138-144.	2.1	7
41	Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, S40-S48.	2.1	7
42	Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions. <i>Vaccine</i> , 2017, 35, 4321-4329.	3.8	6
43	Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. <i>Lancet HIV</i> , 2022, 9, e24-e31.	4.7	6
44	A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa. <i>PLoS ONE</i> , 2017, 12, e0180645.	2.5	5
45	Measles Immunity at 4.5 Years of Age Following Vaccination at 9 and 15-18 Months of Age Among Human Immunodeficiency Virus (HIV)-infected, HIV-exposed-uninfected, and HIV-unexposed Children. <i>Clinical Infectious Diseases</i> , 2019, 69, 687-696.	5.8	5
46	Behavioral Functioning and Quality of Life in South African Children Living with HIV on Antiretroviral Therapy. <i>Journal of Pediatrics</i> , 2020, 227, 308-313.e2.	1.8	5
47	Effect of HIV-exposure and timing of antiretroviral treatment initiation in children living with HIV on antibody persistence and memory responses to Haemophilus influenzae type b and pneumococcal polysaccharide-protein conjugate vaccines. <i>Vaccine</i> , 2020, 38, 2651-2659.	3.8	4
48	Utility of clinical parameters to identify HIV infection in infants below ten weeks of age in South Africa: a prospective cohort study. <i>BMC Pediatrics</i> , 2011, 11, 104.	1.7	3
49	Negative Diagnostic PCR Tests in School-Aged, HIV-Infected Children on Antiretroviral Therapy Since Early Life in Johannesburg, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 381-389.	2.1	3
50	Naive B Cell Output in HIV-Infected and HIV-Uninfected Children. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 33-39.	1.1	2
51	Disclosure to South African children about their own HIV status over time. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-7.	1.2	2
52	Does community support help children take their ART?. <i>The Lancet Child and Adolescent Health</i> , 2017, 1, 160-161.	5.6	1
53	Educational delays among children living with perinatally-acquired HIV in Johannesburg, South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 438-444.	1.2	1
54	Abacavir Dosing in Neonates from Birth to 3 Months of Life. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
55	The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to <math>\hat{A}</math>18 Years. Drug Safety, 2021, 44, 439-446.	3.2	0